The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery s
The present invention provides a compositions and methods for the treatment of cancer, including pancreatic cancer, breast cancer and melanoma, in a human patient. The methods and compositions of the present invention employ curcumin or a curcumin analogue encapsulated in a colloidal drug delivery system, preferably a liposomal drug delivery system. Suitable colloidal drug delivery systems also include nanoparticles, nanocapsules, microparticles or block copolymer micelles. The colloidal drug delivery system encapsulating curcumin or a curcumin analogue is administered parenterally in a pharmaceutically acceptable carrier.
대표청구항▼
1. A method for the treatment or prevention of cancer in a mammalian subject, comprising: a) formulation of a colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite; andb) parenteral administration of the colloidal drug delivery system to a mammalian subj
1. A method for the treatment or prevention of cancer in a mammalian subject, comprising: a) formulation of a colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite; andb) parenteral administration of the colloidal drug delivery system to a mammalian subject in a pharmaceutically acceptable carrier. 2. The method of claim 1, wherein the mammalian subject is a human cancer patient. 3. The method of claim 1, wherein the active ingredient is curcumin, or a curcumin analogue. 4. The method of claim 1, wherein the cancer is pancreatic cancer, melanoma, or a breast cancer. 5. The method of claim 1, wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is lipid-based. 6. The method of claim 5, wherein the lipid-based colloidal drug delivery system comprises liposomes of phosphatidylglycerols selected from at least one of: dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl-phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol, dimyristoylphosphocholine, 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1-acyl-2-acyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], and phosphatidylglycerol 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-1-glycerol), 1,2-dioleoyl-sn-glycero-3-phosphocholine, or combination thereof. 7. The method of claims 1, wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is polymer-based. 8. The method of claim 7, wherein the polymer-based colloidal drug delivery system comprises nanoparticles or nanospheres, microparticles or microspheres, block copolymer micelles, or nanocapsules. 9. The method of claim 1, wherein the colloidal drug delivery system encapsulates curcumin. 10. The method of claim 1, wherein the colloidal drug delivery system encapsulates a curcumin analogue selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 11. A method for the treatment or prevention of cancer in a patient or other mammalian subject, comprising: a) formulation of a non-colloidal polymeric drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite; andb) parenteral administration of the polymeric drug delivery system to a cancer patient in a pharmaceutically acceptable carrier. 12. The method of claim 11, wherein the non-colloidal polymeric drug delivery system comprises a polymeric hydrogel. 13. The method of claim 11, wherein the non-colloidal polymeric drug delivery system comprises a polymeric film. 14. A composition for the treatment or prevention of cancer in a patient or other mammalian subject comprising curcumin, a curcumin analogue or a curcumin metabolite encapsulated in a colloidal drug delivery system in suspension in a pharmaceutically acceptable carrier. 15. The composition of claim 14, wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is lipid-based. 16. The composition of claim 15, wherein the lipid-based colloidal drug delivery system comprises liposomes of phosphatidylglycerols selected from at least one of: dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl-phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol, dimyristoylphosphocholine, 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1-acyl-2-acyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], and phosphatidylglycerol 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-1-glycerol), 1,2-dioleoyl-sn-glycero-3-phosphocholine, or combination thereof. 17. The composition of claim 14, wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or curcumin metabolite is polymer-based, nanoparticles or nanospheres, microparticles or microspheres, block copolymer micelles, or nanocapsules. 18. The composition of claim 14, wherein the colloidal drug delivery system encapsulating curcumin, a curcumin analogue or a curcumin metabolite is a lyophilized powder. 19. The composition of claim 14, wherein the colloidal drug delivery system encapsulates a curcumin analogue selected from the group consisting of Ar-tumerone, methylcurcumin, demethoxy curcumin, bisdemethoxycurcumin, sodium curcuminate, dibenzoylmethane, acetylcurcumin, feruloyl methane, tetrahydrocurcumin, 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione (curcumin), 1,7-bis(piperonyl)-1,6-heptadiene-3,5-dione (piperonyl curcumin) 1,7-bis(2-hydroxy naphthyl)-1,6-heptadiene-2,5-dione (2-hydroxyl naphthyl curcumin) and 1,1-bis(phenyl)-1,3,8,10 undecatetraene-5,7-dione. 20. A composition for the treatment or prevention of cancer in a patient or other mammalian subject comprising curcumin, a curcumin analogue or a curcumin metabolite encapsulated in a liposomes of phosphatidylglycerols selected from at least one of: dilauryloylphosphatidylglycerol, dipalmitoylphosphatidylglycerol, distearoylphosphatidylglycerol, dioleoyl-phosphatidylglycerol, dimyristoylphosphatidylglycerol, palmitoyl-oleoyl-phosphatidylglycerol, dimyristoylphosphocholine, 1,2-diacyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1-acyl-2-acyl-sn-glycero-3-[phospho-rac-(1-glycerol)], 1,2-dimyristoyl-sn-glycero-3-[phospho-rac-(1-glycerol)], and phosphatidylglycerol 1,2-dipalmitoyl-sn-glycero-3-(phospho-rac-1-glycerol), 1,2-dioleoyl-sn-glycero-3-phosphocholine, or combination thereof.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.